Last reviewed · How we verify
Restrictive oxygen
Restrictive oxygen therapy limits supplemental oxygen delivery to maintain lower oxygen saturation targets in hospitalized patients.
Restrictive oxygen therapy limits supplemental oxygen delivery to maintain lower oxygen saturation targets in hospitalized patients. Used for Acute respiratory failure in hospitalized patients, COPD exacerbations, Post-operative respiratory support.
At a glance
| Generic name | Restrictive oxygen |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Respiratory Medicine |
| Phase | FDA-approved |
Mechanism of action
This is a therapeutic strategy rather than a pharmacological drug, involving controlled oxygen administration to avoid hyperoxia and its associated complications. The approach is based on evidence that excessive oxygen can increase oxidative stress, inflammation, and adverse outcomes in certain patient populations, particularly those with critical illness or specific conditions like COPD exacerbations.
Approved indications
- Acute respiratory failure in hospitalized patients
- COPD exacerbations
- Post-operative respiratory support
Common side effects
- Hypoxemia if oxygen targets set too low
- Patient discomfort from lower oxygen saturation
Key clinical trials
- Oxygen Targets in Acute Heart Failure With Pulmonary Congestion (PHASE2, PHASE3)
- Early Detection of Acute Respiratory Failure Using an Intelligent Respiratory Monitoring System
- Evaluation of Alternative Transfusion Triggers in Hemodynamically Stable, Non-Ventilated Cancer Patients
- Fluid Administered According to PVI Versus Fluid Management in Laparoscopic Trendelenburg Surgeries (NA)
- Perfusion Parameters and Outcome During a Standardized Deresuscitation Strategy with Net Ultrafiltration: a Retrospective Cohort Study.
- Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery (PHASE3)
- Restrictive Vs. Liberal Oxygen in Trauma (PHASE4)
- GLP-1 and Hyperoxia for Organ Protection in Heart Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Restrictive oxygen CI brief — competitive landscape report
- Restrictive oxygen updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI